Management of AD With Dupilumab and Topical Corticosteroids Management of AD With Dupilumab and Topical Corticosteroids

This appraisal of a recent study on the efficacy and safety of long-term therapy with dupilumab, the first USFDA approved biological treatment for moderate-to-severe AD, revealed some concerns.The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news